List view / Grid view

Articles

Issue #1 2018

Antibody library screening: high throughput strategies

10 May 2018 | By Emma Cummins - Centre for Drug Research and Development Canada, Gregorio Aversa - Abimmune Technologies Inc., Ismael Samudio - Centre for Drug Research and Development Canada

As the number of antibody discovery platforms and formats expands, various characteristics must be rigorously screened for and taken into consideration when deciding which hits to progress to successful development. The earlier in the antibody discovery pathway the assessment is carried out, the greater the hit enrichment and selection will…

Taking the brakes off the immune system: modelling effects in non-clinical safety studies

2 May 2018 | By Greg Bannish - Vice President Biopharmaceutical Development Envigo

This article focuses on how the immune system functions, the challenges that it presents to drug development and why there are such concerns around safety that need to be investigated in pre-clinical studies. Moreover, it covers the role of checkpoint inhibitors as an attractive target for cancer immunotherapy.

Issue #1 2018

How the study of lipidomics is benefiting from recent advances in mass spectrometry

10 April 2018 | By Cristina Legido-Quigley (Principal Investigator in Systems Medicine at Steno Diabetes Center Copenhagen)

There are no short-cuts in the complex field of lipidomics, explains Cristina Legido-Quigley, a Principal Investigator in Systems Medicine at Steno Diabetes Center Copenhagen in Denmark and at King’s College London.

Issue #1 2018

Lymphocytes armed to kill: how customised cell engineering advances immunotherapy

4 April 2018 | By Drug Target Review

The immune system is now regarded as a powerful weapon in the war against cancer, and in the current era immune cells have become ‘living drugs’. This review article considers some of the key advances in immuno-oncology...

Issue #1 2018

Joseph Zock, Senior Director of Product Management at IntelliCyt Corporation

Expert view: Addressing the big challenges in cell-based assays

21 March 2018 | By Joseph Zock (Senior Director - Product Management - IntelliCyt -a Sartorius Company)

As the drug discovery industry takes on the complex disease states that plague our world, the need for more relevant and timely answers from cell-based assays has become a major challenge.

Issue #1 2018

Expert view: How NGS is continuing to revolutionise our understanding of genomics

21 March 2018 | By Ben Jackson (Associate Director - Marketing - Bioline)

Next generation sequencing (NGS) has transformed biological research, invigorating the field of genomics, and has increased understanding of our genetic basis.

Issue #1 2018

Under the microscope: Choosing the best microplate reader

19 March 2018 | By Mark Wigglesworth (Director High-Throughput Screening - AstraZeneca)

Efficient microplate readers play an important role in effective hit molecule discovery. Mark Wigglesworth, of AstraZeneca, explains what he looks for in this technology.

Issue #1 2018

Expert view: Laboratory informatics software – the top challenges

19 March 2018 | By Laurence Painell (VP Marketing - IDBS)

A look back, and forward, at the key trends within laboratory informatics.

Issue #1 2018

High throughput flow cytometry for multifactorial evaluation of novel therapeutic candidates using an innovative in vitro immunooncology screening platform

19 March 2018 | By IntelliCyt Corporation

This recent webinar focused on the role of IntelliCyt’s iQue Screener PLUS platform as a high throughput suspension cell screening platform to facilitate simultaneous assessment of multiple parameters, while using minimal sample volumes.

Issue #1 2018

Anis H. Khimani, Ph.D., Head of Strategy & Marketing, PerkinElmer

Expert view: Toward physiological relevance in drug discovery and development

19 March 2018 | By Anis H. Khimani (PerkinElmer)

Physiologically relevant screening models have become increasingly important in assay development and the screening of drug candidates.

Issue #1 2018

Streamlining drug discovery assays for cancer and cardiovascular disease

19 March 2018 | By Drug Target Review

Declining R&D productivity is a key challenge in the pharmaceutical industry. To increase the success rate of candidate drugs entering the clinical phase, companies must address the early stages of drug discovery.

Issue #1 2018

Expert view: Screening tools for better lead characterisation

19 March 2018 | By Alessandro Spedito (Global Strategy Manager, CRO and Preclinical presso Merck Group)

Predictiveness is one of the key factors for success in the drug discovery workflow. Many compounds fail at late stages due to lack of predictive data or the discovery of unwanted side effects.

Issue #1 2018

Lab Automation In-Depth Focus 2018

16 March 2018 | By Drug Target Review

In this issue: how lab automation has accelerated pharmaceutical research by simplifying operations, reducing manual tasks and increasing the efficiency, quality and reproducibility of results.

Issue #1 2018

Informatics In-Depth Focus 2018

15 March 2018 | By Drug Target Review

In this In-Depth Focus: enabling research on understudied and unstudied targets, and using multi-omics data to detail drug responses in the human metabolic network.

Issue #1 2018

Drug Target Review #1 2018 Assays In-Depth Focus

Assays In-Depth Focus 2018

14 March 2018 | By Drug Target Review

In this In-Depth Focus: high throughput strategies for antibody library screening, and the latest in vitro 3D cell and tissue culture model systems in HTS.